Brendan P. Eckelman
CIK 1766433 · Chief Scientific Officer · last filed 2024-05-30
Brendan P. Eckelman is a Chief Scientific Officer who has filed 19 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing, for INBXV, was dated May 30, 2024. Across all open-market trades the lifetime net is −$21.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $15.4M across reported positions. 27 SEC filings were submitted jointly with Inhibrx, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INBX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
11025 N. TORREY PINES ROAD, SUITE 200
LA JOLLA, CA 92037
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Inhibrx, Inc. (INBXV) Delisted | Chief Scientific Officer | 0 | — | — | -$10.29M | 1 | 2024-05-30 |
| INBX | Chief Scientific Officer | 160,000 | $96.03 | $15.36M | -$10.76M | 11 | 2024-05-24 |
Recent Filings
19 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-05-30 | Inhibrx, Inc. (INBXV) Delisted | Mixed | −2,355,553 | -$71.96M | EDGAR |
| 2024-05-30 | — | Grant (A) | +513,888 | $0 | |
| 2024-05-28 | — | Notice (144) | −300,000 | -$10.29M | EDGAR |
| 2024-05-24 | INBX | Exer (M) | — | $0 | EDGAR |
| 2024-05-22 | — | Notice (144) | −5,010 | -$170.9K | EDGAR |
| 2024-03-15 | INBX | Exer (M) | — | $0 | EDGAR |
| 2024-03-13 | — | Notice (144) | −1,898 | -$67.1K | EDGAR |
| 2024-03-12 | — | Notice (144) | −24,050 | -$847.9K | EDGAR |
| 2024-03-12 | INBX | Exer (M) | — | $0 | EDGAR |
| 2024-03-11 | — | Notice (144) | −13,558 | -$478.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.